ImmunityBio Launches Phase 1 Study on CAR-NK Cell Therapy
ImmunityBio, Inc. (NASDAQ: IBRX), known for its pioneering work in immunotherapy, proudly announces the commencement of patient dosing in its groundbreaking Phase 1 clinical study. This research explores the potential efficacy of its CAR-NK cell therapy, specifically targeting CD-19 for treating relapsed B-cell Non-Hodgkin lymphoma (NHL). In this initial trial labeled QUILT 106, the focus is on administering CD19-targeted high-affinity natural killer (t-haNK) cells as a standalone treatment before evaluating their effectiveness in combination with the standard NHL therapy, rituximab. This study will involve participants with relapsed or refractory B-cell NHL, enrolled across multiple sites in South Africa, including Johannesburg, Pretoria, and Bloemfontein.
Significance of the CAR-NK Cell Therapy
This is a historic endeavor as it marks the first time a cellular-targeted natural killer cell therapy study is being conducted in South Africa. The clinical study aims to gather crucial information about treating a cancer type that has a notably high incidence rate in the region, yet lacks sufficient treatment options. NHL ranks as the sixth most common cancer in Sub-Saharan Africa, impacting both men and women significantly, according to local cancer associations.
Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio, emphasized the importance of this trial: "This represents a vital step in our research journey, showcasing our commitment to addressing the unmet medical needs of the Sub-Saharan African population, which is frequently overlooked in advanced clinical research."
Study Details and Objectives
The Phase 1 open-label study is structured to include up to 10 participants, with the fundamental objective of evaluating the safety and preliminary efficacy of CAR-NK, CD19 t-haNK cells as both a single agent and in conjunction with rituximab. The protocol involves an initial administration of a single 3-week cycle of the CD19 t-haNK, followed by a 1-week safety assessment before transitioning to the combination treatment with rituximab.
Expected Milestones
Full enrollment for this Phase 1 clinical study is anticipated to conclude in early 2025, with an initial readout of topline data expected to be available later that same year. This progressive timeline showcases ImmunityBio's dedication to expediting research that may lead to innovative treatments in oncology.
Exploring CAR-NK, CD19 t-haNK Cells
The innovative CD19 t-haNK cells are derived from a stable clonal NK cell line, building upon the therapeutic success observed in earlier development phases. These genetically engineered cells express significant proteins that enhance their ability to combat tumors effectively. Their dual targeting approach via CAR and receptor modification is designed to maximize the anti-tumor responses.
Understanding Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma remains a complex disease, primarily affecting B lymphocytes. The incidence statistics indicate that approximately 1 in 174 men and 1 in 288 women are diagnosed with NHL in South Africa, embracing a variety of subtypes and characteristics. Current findings suggest a marked difference in the distribution of NHL types, reflecting a need for extensive research and adapted treatment options tailored to regional demographics.
About ImmunityBio
ImmunityBio is dedicated to developing next-generation therapies and vaccines aimed at enhancing the natural immune system to fight against cancers and infectious diseases. The company’s approach relies on integrated immunotherapy platforms designed for efficacy and safety, with an ongoing commitment to innovation in care standards. Through this study and others, ImmunityBio continues to strive for accessible treatment solutions that are efficient and easy to administer.
Frequently Asked Questions
What is the objective of the CAR-NK cell therapy study?
The study aims to evaluate the safety and preliminary efficacy of CAR-NK, CD19 t-haNK cells in treating relapsed B-cell Non-Hodgkin lymphoma as a single agent and in combination with rituximab.
Where are the study sites located?
The study is being conducted at sites located in Johannesburg, Pretoria, and Bloemfontein, South Africa.
How many participants will be enrolled in the Phase 1 study?
Up to 10 participants are expected to be enrolled in this initial phase of the clinical study.
When is the full enrollment anticipated to be completed?
Full enrollment is expected to be achieved in the first quarter of 2025.
What role does the CAR-NK cell therapy play in NHL treatment?
The CAR-NK cell therapy is intended to enhance treatment options for relapsed B-cell NHL, providing potentially novel therapeutic avenues for patients who have limited treatment choices.
